T_Dia
05-14-2009, 01:44 PM
Patients with type 2 diabetes may have a new treatment option: bromocriptine mesylate, a drug that manages blood glucose via brain signals and targets the central nervous system. The drug has been approved by the FDA and will be marketed as Cycloset, according to drug maker VeroScience.
The dopamine receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults with diabetes. Bromocriptine mesylate is not a new drug — it has been used in different formulations to treat conditions such as Parkinson’s disease.
Thirty-nine percent of patients with type 2 diabetes assigned to bromocriptine mesylate achieved target glycemic control compared with 11% of patients assigned to placebo in the Cycloset Safety Trial, a 52-week, placebo-controlled trial (n=3,070).
Full Article (http://www.endocrinetoday.com/view.aspx?rid=39696).
The dopamine receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults with diabetes. Bromocriptine mesylate is not a new drug — it has been used in different formulations to treat conditions such as Parkinson’s disease.
Thirty-nine percent of patients with type 2 diabetes assigned to bromocriptine mesylate achieved target glycemic control compared with 11% of patients assigned to placebo in the Cycloset Safety Trial, a 52-week, placebo-controlled trial (n=3,070).
Full Article (http://www.endocrinetoday.com/view.aspx?rid=39696).